Mr. Shawn Overtond reports

CHROMEDX ANNOUNCES COMPLETION OF HEMOPALM(TM) PROTOTYPE CARTRIDGE

ChroMedX Corp. has completed the HemoPalm system prototype cartridge.

In conjunction with the previously announced Engage grant with McMaster University's Manufacturing Research Institute (MMRI), the company has completed the fabrication of the prototype HemoPalm cartridge, a key component of the HemoPalm analysis system. MMRI produced the prototype by micromachining and testing of cartridge operation, including calibration fluid pouch activation, and microfluidic flow has already begun. Development of co-oximetry calibration algorithms at McMaster University is under way.

"This is the first major step in the completion of the HemoPalm system alpha prototype. The cartridge is a critical element of the system and contains several novel features that set it apart from competitive products. Micromachining of the prototype cartridges has allowed rapid design modifications when needed, avoiding the time and cost of modifications to conventional plastic injection moulds. We are very pleased with our collaboration with McMaster University," said Dr. Wayne Maddever, president and chief executive officer of ChroMedX.

The company is also pleased to present a 3-D schematic video of the HemoPalm analyzer system, which demonstrates the sequence of operations commencing with the scanning of the cartridge for identification, followed by spectroscopic co-oximetry measurement, biosensor fluid calibration, and biosensor measurement of blood gases and electrolytes.

ChroMedX recently announced the engagement of Polygenesis Corp. to complete the development of the biosensor technology aspect of the HemoPalm system, as well as complete the development of the prototype analyzer.

We seek Safe Harbor.